Skip to main content
Top
Published in: Tumor Biology 2/2016

01-02-2016 | Original Article

The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma

Authors: Xiao-li Wei, Dong-sheng Zhang, Ming-ming He, Ying Jin, De-shen Wang, Yi-xin Zhou, Long Bai, Zhe-zhen Li, Hui-yan Luo, Feng-hua Wang, Rui-hua Xu

Published in: Tumor Biology | Issue 2/2016

Login to get access

Abstract

The elevation of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) has been demonstrated to predict worse prognosis in various malignancies; however, their prognostic value in esophageal squamous cell carcinoma has not been well studied. We conducted a retrospective study of 906 patients with esophageal squamous cell carcinoma to explore their prognostic value for overall survival. The optimal cutoff points for ALP and LDH were determined. We analyzed the association between the levels of ALP and LDH and clinicopathological characteristics. Their prognostic value for overall survival was explored by univariate and multivariate analysis. We also proposed the ALP and LDH classification and examined its prognostic value in the general population and subgroups. The optimal cutoff points of ALP and LDH to predict overall survival were 90.7 and 361.5 U/L respectively. Higher levels of ALP and LDH were both associated with more advanced TNM stage (P = 0.003 and 0.002, respectively) and more distant metastasis (P = 0.001 and P < 0.001, respectively). Both ALP (≤90.7/>90.7 U/L) and LDH (≤361.5/>361.5 U/L) were independent prognostic factors for overall survival in esophageal squamous cell carcinoma (P = 0.004 and P < 0.001 by multivariate analysis). The ALP and LDH classification categorized patients into three subgroups with distinct prognosis (P < 0.001 by multivariate analysis) and identified a small group of patients who had extremely poor overall survival with a median of 4.2 months. In conclusion, ALP and LDH were both independent prognostic factors for overall survival. A combination of the two indexes might contribute to further identification of survival differences in esophageal squamous cell carcinoma.
Literature
1.
go back to reference Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, Wei W, Inoue M, Tanaka H. Epidemiology of esophageal cancer in Japan and China, vol. 23, 2013:233–42. Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, Wei W, Inoue M, Tanaka H. Epidemiology of esophageal cancer in Japan and China, vol. 23, 2013:233–42.
2.
go back to reference Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut 2014. Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut 2014.
3.
go back to reference Rice TW, Rusch VW, Ishwaran H, Blackstone EH. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 2010;116:3763–73.CrossRefPubMed Rice TW, Rusch VW, Ishwaran H, Blackstone EH. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 2010;116:3763–73.CrossRefPubMed
4.
go back to reference Maisano R, Azzarello D, Del MP, Maisano M, Bottari M, Egitto G, et al. Alkaline phosphatase levels as a prognostic factor in metastatic colorectal cancer treated with the FOLFOX 4 regimen: a monoinstitutional retrospective study. Tumori. 2011;97:39–42.PubMed Maisano R, Azzarello D, Del MP, Maisano M, Bottari M, Egitto G, et al. Alkaline phosphatase levels as a prognostic factor in metastatic colorectal cancer treated with the FOLFOX 4 regimen: a monoinstitutional retrospective study. Tumori. 2011;97:39–42.PubMed
5.
go back to reference Sonpavde G, Pond GR, Berry WR, de Wit R, Armstrong AJ, Eisenberger MA, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol. 2012;30:607–13.CrossRefPubMed Sonpavde G, Pond GR, Berry WR, de Wit R, Armstrong AJ, Eisenberger MA, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol. 2012;30:607–13.CrossRefPubMed
6.
go back to reference Xie W, Nakabayashi M, Regan MM, Oh WK. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase. Cancer. 2007;110:2709–15.CrossRefPubMed Xie W, Nakabayashi M, Regan MM, Oh WK. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase. Cancer. 2007;110:2709–15.CrossRefPubMed
7.
go back to reference Xie Y, Wei ZB, Duan XW. Prognostic value of pretreatment serum alkaline phosphatase in nasopharyngeal carcinoma. Asian Pac J Cancer Prev. 2014;15:3547–53.CrossRefPubMed Xie Y, Wei ZB, Duan XW. Prognostic value of pretreatment serum alkaline phosphatase in nasopharyngeal carcinoma. Asian Pac J Cancer Prev. 2014;15:3547–53.CrossRefPubMed
8.
go back to reference Sagman U, Feld R, Evans WK, Warr D, Shepherd FA, Payne D, et al. The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer. J Clin Oncol. 1991;9:954–61.CrossRefPubMed Sagman U, Feld R, Evans WK, Warr D, Shepherd FA, Payne D, et al. The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer. J Clin Oncol. 1991;9:954–61.CrossRefPubMed
9.
go back to reference Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol. 2012;30:3402–7.CrossRefPubMed Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol. 2012;30:3402–7.CrossRefPubMed
10.
go back to reference Brown JE, Cook RJ, Lipton A, Coleman RE. Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients. Clin Cancer Res. 2012;18:6348–55.CrossRefPubMed Brown JE, Cook RJ, Lipton A, Coleman RE. Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients. Clin Cancer Res. 2012;18:6348–55.CrossRefPubMed
11.
go back to reference Wei Z, Zeng X, Xu J, Duan X, Xie Y. Prognostic value of pretreatment serum levels of lactate dehydrogenase in nonmetastatic nasopharyngeal carcinoma: single-site analysis of 601 patients in a highly endemic area. Onco Targets Ther. 2014;7:739–49.CrossRefPubMedPubMedCentral Wei Z, Zeng X, Xu J, Duan X, Xie Y. Prognostic value of pretreatment serum levels of lactate dehydrogenase in nonmetastatic nasopharyngeal carcinoma: single-site analysis of 601 patients in a highly endemic area. Onco Targets Ther. 2014;7:739–49.CrossRefPubMedPubMedCentral
12.
go back to reference Yamada Y, Nakamura K, Aoki S, Tobiume M, Zennami K, Kato Y, et al. Lactate dehydrogenase, Gleason score and HER-2 overexpression are significant prognostic factors for M1b prostate cancer. Oncol Rep. 2011;25:937–44.CrossRefPubMed Yamada Y, Nakamura K, Aoki S, Tobiume M, Zennami K, Kato Y, et al. Lactate dehydrogenase, Gleason score and HER-2 overexpression are significant prognostic factors for M1b prostate cancer. Oncol Rep. 2011;25:937–44.CrossRefPubMed
13.
go back to reference Huang JJ, Cai MY, Ye S, Li ZM, Huang HQ, Lin TY. Clinical analysis of 19 cases of subcutaneous panniculitis T-cell lymphoma with literature review. Ai Zheng. 2009;28:1093–9.PubMed Huang JJ, Cai MY, Ye S, Li ZM, Huang HQ, Lin TY. Clinical analysis of 19 cases of subcutaneous panniculitis T-cell lymphoma with literature review. Ai Zheng. 2009;28:1093–9.PubMed
14.
go back to reference Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer—pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22:2395–403.CrossRefPubMed Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer—pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22:2395–403.CrossRefPubMed
15.
go back to reference Polee MB, Hop WC, Kok TC, Eskens FA, van der Burg ME, Splinter TA, et al. Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer. 2003;89:2045–50.CrossRefPubMedPubMedCentral Polee MB, Hop WC, Kok TC, Eskens FA, van der Burg ME, Splinter TA, et al. Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer. 2003;89:2045–50.CrossRefPubMedPubMedCentral
16.
go back to reference Alici S, Ugras S, Bayram I, Izmirli M. Prognostic factors and COX-2 expression in advanced stage esophageal squamous cell carcinoma. Adv Ther. 2006;23:672–9.CrossRefPubMed Alici S, Ugras S, Bayram I, Izmirli M. Prognostic factors and COX-2 expression in advanced stage esophageal squamous cell carcinoma. Adv Ther. 2006;23:672–9.CrossRefPubMed
17.
go back to reference Zhang P, Xi M, Li QQ, He LR, Liu SL, Zhao L, et al. The modified Glasgow prognostic score is an independent prognostic factor in patients with inoperable thoracic esophageal squamous cell carcinoma undergoing chemoradiotherapy. J Cancer Educ. 2014;5:689–95.CrossRef Zhang P, Xi M, Li QQ, He LR, Liu SL, Zhao L, et al. The modified Glasgow prognostic score is an independent prognostic factor in patients with inoperable thoracic esophageal squamous cell carcinoma undergoing chemoradiotherapy. J Cancer Educ. 2014;5:689–95.CrossRef
18.
go back to reference Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7, e51862.CrossRefPubMedPubMedCentral Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7, e51862.CrossRefPubMedPubMedCentral
19.
go back to reference Zhang SS, Yang H, Luo KJ, Huang QY, Chen JY, Yang F, et al. The impact of body mass index on complication and survival in resected oesophageal cancer: a clinical-based cohort and meta-analysis. Br J Cancer. 2013;109:2894–903.CrossRefPubMedPubMedCentral Zhang SS, Yang H, Luo KJ, Huang QY, Chen JY, Yang F, et al. The impact of body mass index on complication and survival in resected oesophageal cancer: a clinical-based cohort and meta-analysis. Br J Cancer. 2013;109:2894–903.CrossRefPubMedPubMedCentral
20.
go back to reference Feng JF, Chen QX. Significance of the prognostic nutritional index in patients with esophageal squamous cell carcinoma. Ther Clin Risk Manag. 2014;10:1–7.PubMed Feng JF, Chen QX. Significance of the prognostic nutritional index in patients with esophageal squamous cell carcinoma. Ther Clin Risk Manag. 2014;10:1–7.PubMed
21.
go back to reference Feng JF, Huang Y, Liu JS. Combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma. Onco Targets Ther. 2013;6:1605–12.PubMedPubMedCentral Feng JF, Huang Y, Liu JS. Combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma. Onco Targets Ther. 2013;6:1605–12.PubMedPubMedCentral
22.
go back to reference Turen S, Ozyar E, Altundag K, Gullu I, Atahan IL. Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Cancer Investig. 2007;25:315–21.CrossRef Turen S, Ozyar E, Altundag K, Gullu I, Atahan IL. Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Cancer Investig. 2007;25:315–21.CrossRef
23.
go back to reference Weiss MJ, Ray K, Henthorn PS, Lamb B, Kadesch T, Harris H. Structure of the human liver/bone/kidney alkaline phosphatase gene. J Biol Chem. 1988;263:12002–10.PubMed Weiss MJ, Ray K, Henthorn PS, Lamb B, Kadesch T, Harris H. Structure of the human liver/bone/kidney alkaline phosphatase gene. J Biol Chem. 1988;263:12002–10.PubMed
24.
go back to reference Xu XS, Wan Y, Song SD, Chen W, Miao RC, Zhou YY, et al. Model based on gamma-glutamyltransferase and alkaline phosphatase for hepatocellular carcinoma prognosis. World J Gastroenterol. 2014;20:10944–52.CrossRefPubMedPubMedCentral Xu XS, Wan Y, Song SD, Chen W, Miao RC, Zhou YY, et al. Model based on gamma-glutamyltransferase and alkaline phosphatase for hepatocellular carcinoma prognosis. World J Gastroenterol. 2014;20:10944–52.CrossRefPubMedPubMedCentral
25.
go back to reference Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94:1760–9.CrossRefPubMed Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94:1760–9.CrossRefPubMed
26.
go back to reference Zhang M, Yan X, Zhang F. Expression of placental alkaline phosphatase in esophageal cancer cell line Eca109. Zhonghua Zhong Liu Za Zhi. 1996;18:186–8.PubMed Zhang M, Yan X, Zhang F. Expression of placental alkaline phosphatase in esophageal cancer cell line Eca109. Zhonghua Zhong Liu Za Zhi. 1996;18:186–8.PubMed
27.
go back to reference Ali NN, Rowe J, Teich NM. Constitutive expression of non-bone/liver/kidney alkaline phosphatase in human osteosarcoma cell lines. J Bone Miner Res. 1996;11:512–20.CrossRefPubMed Ali NN, Rowe J, Teich NM. Constitutive expression of non-bone/liver/kidney alkaline phosphatase in human osteosarcoma cell lines. J Bone Miner Res. 1996;11:512–20.CrossRefPubMed
28.
go back to reference Tokumitsu SI, Tokumitsu K, Kohnoe K, Takeuchi T. Characterization of liver-type alkaline phosphatase from human gastric carcinoma cells (KMK-2) in vitro. Cancer Res. 1979;39:4732–8.PubMed Tokumitsu SI, Tokumitsu K, Kohnoe K, Takeuchi T. Characterization of liver-type alkaline phosphatase from human gastric carcinoma cells (KMK-2) in vitro. Cancer Res. 1979;39:4732–8.PubMed
29.
go back to reference Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol. 2014;8:1095–111.CrossRefPubMed Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol. 2014;8:1095–111.CrossRefPubMed
30.
go back to reference Kogo M, Suzuki A, Kaneko K, Yoneyama K, Imawari M, Kiuchi Y. Scoring system for predicting response to chemoradiotherapy, including 5-fluorouracil and platinum, for patients with esophageal cancer. Dig Dis Sci. 2008;53:2415–21.CrossRefPubMed Kogo M, Suzuki A, Kaneko K, Yoneyama K, Imawari M, Kiuchi Y. Scoring system for predicting response to chemoradiotherapy, including 5-fluorouracil and platinum, for patients with esophageal cancer. Dig Dis Sci. 2008;53:2415–21.CrossRefPubMed
32.
go back to reference Baggstrom MQ, Qi Y, Koczywas M, Argiris A, Johnson EA, Millward MJ, et al. A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol. 2011;6:1757–60.CrossRefPubMedPubMedCentral Baggstrom MQ, Qi Y, Koczywas M, Argiris A, Johnson EA, Millward MJ, et al. A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol. 2011;6:1757–60.CrossRefPubMedPubMedCentral
33.
go back to reference Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res. 2009;15:3172–6.CrossRefPubMedPubMedCentral Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res. 2009;15:3172–6.CrossRefPubMedPubMedCentral
34.
go back to reference Han X, Sheng X, Jones HM, Jackson AL, Kilgore J, Stine JE, et al. Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells. J Hematol Oncol. 2015;8:2.CrossRefPubMedPubMedCentral Han X, Sheng X, Jones HM, Jackson AL, Kilgore J, Stine JE, et al. Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells. J Hematol Oncol. 2015;8:2.CrossRefPubMedPubMedCentral
Metadata
Title
The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma
Authors
Xiao-li Wei
Dong-sheng Zhang
Ming-ming He
Ying Jin
De-shen Wang
Yi-xin Zhou
Long Bai
Zhe-zhen Li
Hui-yan Luo
Feng-hua Wang
Rui-hua Xu
Publication date
01-02-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3851-y

Other articles of this Issue 2/2016

Tumor Biology 2/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine